GENEVA, SWITZERLAND / ACCESSWIRE / October 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (“Reduction”), immediately introduced that they and NRx Prescribed drugs, Inc. (“NRx”) have agreed to increase the keep of their pending litigation till November 7, 2022 to permit time for the events to finalize their tentative litigation settlement. There could be no assurance that the events will efficiently full their proposed settlement.
About Reduction Therapeutics
Reduction is a Swiss, commercial-stage, biopharmaceutical firm targeted on identification, growth and commercialization of novel, patent protected merchandise meant for the remedy of uncommon and ultra-rare ailments together with metabolic issues, pulmonary ailments, and connective tissue issues. Reduction’s diversified pipeline consists of property which have the potential to successfully deal with vital unmet medical wants, together with PKU GOLIKE ® , engineered with Reduction’s proprietary Physiomimic know-how, which is the primary prolonged-release amino acid product commercialized for the dietary administration of phenylketonuria (“PKU”). Reduction has a Collaboration and License Settlement with Acer Therapeutics for the worldwide growth and commercialization of ACER-001 (sodium phenylbutyrate) for the remedy of varied inborn errors of metabolism, together with Urea Cycle Issues (“UCDs”) and Maple Syrup Urine Illness (“MSUD”). Reduction additionally continues to develop aviptadil for a number of uncommon pulmonary indications. Additional, Reduction is in medical growth for APR-TD011, a differentiated acid oxidizing resolution of hypochlorous acid meant for the remedy of epidermolysis bullosa (“EB”), a gaggle of uncommon, genetic, life-threatening connective tissue issues; APR-TD011 has been granted Orphan Drug Designation by the FDA. Lastly, Reduction is commercializing a number of legacy merchandise through licensing and distribution companions.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Trade below the image RLF and quoted within the U.S. on OTCQB below the symbols RLFTF and RLFTY. For extra info, go to www.relieftherapeutics.com . Comply with Reduction on LinkedIn .
Ahead-Wanting Statements
This press launch accommodates forward-looking statements. Ahead-looking statements contain recognized and unknown dangers and uncertainties, which can trigger precise leads to future intervals to vary materially from forecasted outcomes. Numerous components, together with (i) whether or not Reduction and NRx will efficiently full their proposed litigation settlement, and (ii) these components described in Reduction’s filings with the SIX Inventory Trade and the U.S. Securities and Trade Fee that would adversely have an effect on Reduction. Copies of Reduction’s filings with the SEC can be found on the SEC EDGAR database at www.sec.gov . Reduction doesn’t undertake any obligation to replace the knowledge contained herein, which speaks solely as of this date.
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack Weinstein
Chief Monetary Officer and Treasurer
[email protected]
FOR MEDIA/INVESTOR INQUIRIES:
LifeSci Advisors
Irina Koffler
(917) 734-7387
[email protected]
SOURCE: Reduction Therapeutics Holdings AG
View supply model on accesswire.com:
https://www.accesswire.com/722339/RELIEF-THERAPEUTICS-Holding-SA-and-NRx-Prescribed drugs-Inc-Prolong-Their-Keep-of-Pending-Litigation-to-Present-Further-Time-for-The-Events-to-Finalize-Their-Settlement
